Pacira BioSciences issues inducement equity grants to five new hires

Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards to five new employees on September 2, 2026, as disclosed in a filing reported by GN stocks. The awards, issued under the company’s Amended and Restated 2014 Inducement Plan, were approved by the People & Compensation Committee without a shareholder vote, consistent with Nasdaq Listing Rule 5635(c)(4). This mechanism allows the company to secure specific talent by offering equity compensation that is immediately material to the employee’s decision to join.

The equity package comprises stock options for three employees covering 8,900 shares and restricted stock units (RSUs) for all five hires totaling 14,000 shares. The stock options carry an exercise price of $26.58 per share, matching the closing price of PCRX on the Nasdaq Global Select Market on the grant date. These options have a ten-year term and vest over four years, with 25% of the underlying shares becoming exercisable on the first anniversary of employment and the remainder vesting in equal quarterly installments over the following 36 months.

Vesting mechanics tie equity to service

The restricted stock unit awards vest annually in four equal installments, with the first tranche becoming eligible on September 1, 2027. Each RSU represents the contingent right to receive one share of Pacira common stock. Both the options and the RSUs are subject to the employee’s continued employment with the company, meaning that departure prior to vesting results in the forfeiture of unvested awards. This structure aligns the financial interests of new hires with long-term company performance.

Pacira focuses on non-opioid pain therapies

Pacira BioSciences positions itself as a leader in non-opioid pain management, currently commercializing two primary products. EXPAREL, a long-acting local analgesic, is approved for various nerve blocks to manage postsurgical pain. ZILRETTA, an extended-release intra-articular injection, is indicated for osteoarthritis knee pain. The company’s pipeline includes PCRX-201, a gene therapy candidate for knee osteoarthritis currently in Phase 2 clinical development.

Regulatory compliance for inducement grants

The use of the inducement plan allows Pacira to issue equity to new hires without delaying the hiring process for shareholder approval, which is typically required for broader equity compensation plans. This provision is critical for companies operating in competitive talent markets, particularly in biotechnology and pharmaceuticals. The specific terms of each award are governed by individual award agreements, ensuring that the grants comply with internal governance standards and external regulatory requirements.